human colorectal cancer cell line ht29 (Servicebio Inc)
Structured Review

Human Colorectal Cancer Cell Line Ht29, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human colorectal cancer cell line ht29/product/Servicebio Inc
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer"
Article Title: Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer
Journal: Cancer Drug Resistance
doi: 10.20517/cdr.2025.35
Figure Legend Snippet: Identification of potential biomarkers predicting bevacizumab efficacy in CRC. (A) Scatter plot of upregulated differential expression genes (DEGs) in pre-treated colorectal cancer compared to mucosa in bevacizumab responders in dataset GSE60331 . The DEGs were ranked in descending order by logFC along the X-axis. The color depth represents -log(adjusted P -value); (B) Scatter plot of upregulated differential expression genes (DEGs) in pre-treated colorectal cancer compared to mucosa in bevacizumab non-responders in dataset GSE60331 . The DEGs were ranked in descending order by logFC along the X-axis. The color depth represents -log(adjusted P -value); (C) Venn diagram of DEGs in responders and non-responders; (D) Scatter plot of -log( P -value) from two survival analyses. The X-axis represents the -log( P -value) of the hazard ratio (HR) in the Cox proportional hazard model, and the Y-axis represents the -log( P -value) of the Log-rank test. The genes were marked with different colors and were ranked by risk to patient survival in descending order on the right side of the plot based on a combination of -log( P -value) values on the X-axis and Y-axis; (E and F) The expression of MAGEA3 (E) and ANGPT2 (F) in colorectal cancer and normal colon tissue in TCGA database. DEGs: differential expression genes; FC: fold change; HR: hazard ratio.
Techniques Used: Quantitative Proteomics, Expressing
Figure Legend Snippet: Exploring MAGEA3 expression in mice CRC and human CRC samples. (A) The mRNA level of MAGEA3 in tumor and peri-tumor colon tissues from AOM/DSS-treated mice compared to colon tissues in untreated mice; (B) The mRNA level of MAGEA3 in different human CRC cell lines HCT116, Caco-2, and HT29, compared to normal colon epithelial cell line FHC; (C and D) Images and quantification of Western blot of MAGEA3 in tumor and peri-tumor colon tissues from AOM/DSS-treated mice compared to colon tissues from untreated mice; (E and F) Representative images and quantification of immunohistochemistry staining of MAGEA3 in tumor and peri-tumor tissues of human CRC (scale bar: 100 μm). ns: no significance, * P < 0.05, ** P < 0.01, **** P < 0.0001. CRC: colorectal cancer; AOM: azoxymethane; DSS: dextran sulfate sodium.
Techniques Used: Expressing, Western Blot, Immunohistochemistry, Staining
Figure Legend Snippet: MAGEA3 inhibits VEGF expression in CRC. (A) The mRNA level of VEGF in the shNC and shMAGEA3 groups of HCT116 cells, and the EGFP and MAGEA3-OE groups of HT29 cells; (B and C) Representative images and quantification of Western blot of VEGF in medium of the shNC and shMAGEA3 groups of HCT116 cells, and the EGFP and MAGEA3-OE groups of HT29 cells cultured in serum-free medium for 24 h. Ponceau S staining was used as an internal loading control alongside Western blot detection of VEGF; (D) Representative immunohistochemistry (IHC) staining images of MAGEA3 and VEGF in human colorectal cancer (scale bar: 100 μm); (E) Correlation between the IHC scores of MAGEA3 and VEGF in human CRC. * P < 0.05, ** P < 0.01, **** P < 0.0001. shNC: shRNA for negative control; MAGEA3-OE: MAGEA3 overexpression; IHC: immunohistochemistry.
Techniques Used: Expressing, Western Blot, Cell Culture, Staining, Control, Immunohistochemistry, shRNA, Negative Control, Over Expression
Figure Legend Snippet: Rapamycin impacts the inhibitory effect of MAGEA3 on VEGF expression. (A and B) Western blot and quantification of phosphorylated mTOR protein level and total mTOR protein level after knocking down MAGEA3 in HCT116 cells and overexpression of MAGEA3 in HT29 cells; (C) mRNA levels of VEGF in shNC and shMAGEA3 HCT116 cell lines treated or untreated with rapamycin (rapa); (D) mRNA levels of VEGF in EGFP and MAGEA3 overexpression HT29 cell lines treated or untreated with rapamycin. ns: no significance, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. shNC: shRNA for negative control; MAGEA3-OE: MAGEA3 overexpression; rapa: rapamycin.
Techniques Used: Expressing, Western Blot, Over Expression, shRNA, Negative Control
Figure Legend Snippet: MAGEA3 does not activate PDGF, FGF and ANGPT2 in CRC cell lines. (A-C) mRNA levels of PDGF (A), FGF (B), and ANGPT2 (C) in shNC and shMAGEA3 HCT116 cell lines in normoxia and hypoxia & glucose-deprived (Glu(-)) conditions; (D-F) mRNA levels of PDGF (D), FGF (E), and ANGPT2 (F) in HT29 cell lines overexpressing EGFP and MAGEA3 in normoxia and hypoxia & glucose-deprived conditions. ns: no significance, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. shNC: shRNA for negative control; MAGEA3-OE: MAGEA3 overexpression; Glu(-): glucose-deprived; PDGF: Platelet-derived growth factor; FGF: Fibroblast growth factor; ANGPT2: Angiopoietin-2.
Techniques Used: shRNA, Negative Control, Over Expression, Derivative Assay
Figure Legend Snippet: MAGEA3 regulates the mitochondrial capacity of CRC cell lines. (A and B) The extracellular acidification rate (A) and oxygen consumption rate (B) of shNC and shMAGEA3 HCT116 cell lines in Seahorse experiment; (C and D) The extracellular acidification rate (C) and oxygen consumption rate (D) of HT29 cell lines overexpressing EGFP and MAGEA3 in Seahorse experiment. ns: no significance, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. shNC: shRNA for negative control; MAGEA3-OE: MAGEA3 overexpression.
Techniques Used: shRNA, Negative Control, Over Expression

